May 9, 2013
With reference to earlier announcement dated March 28, 2013 regarding proposed reduction of promoter’s shareholding in the Company through the Stock Exchange mechanism, Further, Novartis India Ltd...
April 11, 2013
Why genuine innovators should welcome the Supreme Court’s Glivec judgment.
Mumbai, April 3
Thirty-one-year-old Ashwani Aggarwal followed the legal developments on Novartis blood-cancer drug Glivec, not because he is a medical professional turned pharmaceutical consultant. Last...
Mumbai, April 2
“No way will drug companies move out of India because of Supreme Court ruling against Novartis. They need our (Indian) market and (they) will find ways to sell drug cheaper,” tweeted international...
Mumbai/Hyderabad, April 1
Marks affordable access to medicines in developing countries
New Delhi, Apr 1
Poor patients will have easier access to quality medicines with the Supreme Court rejecting Swiss firm Novartis’ patent plea for its cancer drug Glivec, according to domestic manufacturers.
Mumbai/Coimbatore, April 1
Cancer drug fails to meet requirement of ‘new invention’, rules Supreme Court
New Delhi, March 31
The Supreme Court will pronounce tomorrow its verdict on Swiss pharma giant Novartis AG’s plea for getting its blood cancer drug Glivec patented in India and restraining Indian companies from manu...
Mumbai, May 13
Novartis India has announced the next edition of the Novartis Biotechnology Leadership Camp (BioCamp) taking place in Hyderabad from July 8-10, 2013.
BioCamp is a seminar orga...
April 12, 2013
Proposed clauses in the EU-India FTA could undo all gains from the Supreme Court’s Glivec ruling. »
April 3, 2013
The judgment of the Supreme Court of India on the Novartis patent matter comes at a very crucial juncture . Though the last amendment to the Indian Patents Act 1970 was enacted in 2005, many of it...
Washington, April 3
The US industry today said it is reviewing the order of the Supreme Court early this week that denied patent on Glivec, a cancer medication produced by Swiss drug maker Novartis, as Corporate Amer...
Mumbai, April 1
Does the Supreme Court’s dismissal of Novartis’ plea send out worrying signals that India does not protect original research and intellectual property? Will it spurn foreign companies lo...
Mumbai, April 1
Analysts bullish on Lupin, Sun Pharma, Dr Reddy’s Lab
New Delhi, April 1
Commerce and Industry Minister Anand Sharma has termed as “historic’’ the Supreme Court’s judgement rejecting Swiss pharma major Novartis’ plea for a patent on an improved version...
Mumbai, March 31
At the heart of the case is the interpretation of Section 3 (d) of the amended Patent Act which does not recognise incremental innovation. The Act allows patent protection only for totally new or improved drugs. »
March 28, 2013
Novartis India Ltd has informed BSE that the Company has received a letter dated March 27, 2013 from Novartis AG, Basel, the promoter company of Novartis India Limited informing the Company that it...